Optimal strategy in managing advanced melanoma.

Abstract excerpt

The advent of immune checkpoint inhibitors and combination therapy with BRAF inhibitors and MEK inhibitors has dramatically improved the prognosis of advanced melanoma. However, since acral melanoma and mucosal melanoma, which are rare in Western countries but are major subtypes of melanoma in East Asia, including Japan, have a low frequency of BRAF mutations, there are currently no treatment options other than...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Immune Checkpoint Inhibitors
• Share to Melanoma
• Share to Mutation